- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02290951
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies (ELM-1)
An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Expanded Access
Contacts and Locations
Study Contact
- Name: Clinical Trials Administrator
- Email: clinicaltrials@regeneron.com
Study Locations
-
-
-
Lyon, France, 69495
- Chu Hopital Lyon Sud
-
-
Haute-Normandie
-
Rouen, Haute-Normandie, France, 76038
- Centre Henri Becquerel
-
-
Île-de-France
-
Villejuif, Île-de-France, France, 94800
- Institut Gustave Roussy
-
-
-
-
Bayern
-
Wurzburg, Bayern, Germany, 97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Haifa, Israel, 3436212
- Lady Davis Carmel Medical Center
-
Haifa, Israel, 3109601
- Rambam Health Care Campus - Hematology and Bone Marrow Transplantation Institute
-
-
HaDarom
-
Ashdod, HaDarom, Israel, 7747629
- Assuta Ashdod University Hospital
-
-
HaMerkaz
-
Kfar Saba, HaMerkaz, Israel, 44281
- Meir Medical Center
-
Tel-Hashomer, HaMerkaz, Israel, 5265601
- The Chaim Sheba Medical Center
-
-
Yerushalayim
-
Jerusalem, Yerushalayim, Israel, 9112001
- Hadassah Medical Center
-
-
-
-
-
Manchester, United Kingdom, M20 4BX
- The Christie Nhs Foundation Trust
-
-
Cornwall
-
Truro, Cornwall, United Kingdom, tr1 3lq
- Royal Cornwall Hospitals NHS Trust
-
-
-
-
California
-
Orange, California, United States, 92868
- University of California, Irvine
-
Stanford, California, United States, 94305
- Stanford University
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
Have documented CD20+ B-cell malignancy, with active disease not responsive to prior therapy, for whom no standard of care options exists, and for whom treatment with an anti-CD20 antibody may be appropriate:
- Part A (IV administration) B-NHL confirmed by National Cancer Institute (NCI) working group criteria
- Part B (SC administration): Confirmed diagnosis of B-NHL requiring therapy as defined by WHO classification 2017
Patients with B-NHL must have had prior treatment with an anti-CD20 antibody therapy. Patients with CLL (Part A only) are not required to have received prior treatment with an anti-CD20 antibody therapy as defined in the protocol.
- For the inclusion in the disease-specific expansion cohort enrolling DLBCL patients after failure of CAR-T therapy, the patient must have recovered from the toxicities of the lymphodepletion therapy and CAR-T infusion.
- For inclusion in Part B, patients must have FL grade 1-3a or DLBCL (with or without prior CAR-T) per the criteria above, and:
- Patients with FL grade 1-3a and DLBCL must have received at least 2 prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent
- All patients must have at least one bi-dimensionally measurable lesion ≥1.5 cm) documented by CT or MRI scan, if CT scan is not feasible.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- Life expectancy of at least 6 months
- Adequate bone marrow function as described in the protocol
- Adequate organ function as described in the protocol
- Willingness to undergo mandatory tumor biopsy pretreatment, if in the opinion of the investigator, the patient has an accessible lesion that can be biopsied without significant risk to the patient.
- Willing and able to comply with clinic visits and study-related procedures
- Provide signed informed consent or legally acceptable representative
Key Exclusion Criteria:
- Primary central nervous system (CNS) lymphoma or known or suspected CNS involvement by non-primary CNS NHL
History of or current relevant CNS pathology such as
- Epilepsy, seizure, paresis, aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis, or
- Evidence for presence of inflammatory lesions and/or vasculitis on cerebral MRI
- Standard anti-lymphoma chemotherapy (non-biologic) or radiotherapy within 28 days prior to first administration of study drug
Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or cytomegalovirus (CMV) infection [(as noted by detectable levels on a blood polymerase chain reaction (PCR) assay)].
- Patients with hepatitis B (HepBsAg+) who have controlled infection (serum hepatitis B virus deoxyribonucleic acid (DNA) that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted upon consultation with the physician managing the infection.
- Patients who show detectable levels of CMV at screening will need to be treated with appropriate antiviral therapy and demonstrate at least 2 undetectable levels of CMV by PCR assay (at least 7 days apart) before being re-considered for eligibility.
- Patients who have received a live vaccination within 28 days of first dose of study treatment
Note: Other protocol Inclusion/Exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A
DLBCL post CAR-T
|
Administered by intravenous (IV) infusion
Other Names:
Administered by subcutaneous (SC) injection
Other Names:
|
Experimental: 1N Part B
FL
|
Administered by intravenous (IV) infusion
Other Names:
Administered by subcutaneous (SC) injection
Other Names:
|
Experimental: 2N Part B
DLBCL
|
Administered by intravenous (IV) infusion
Other Names:
Administered by subcutaneous (SC) injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety/overall frequency of adverse events (AEs)
Time Frame: Up to 24 months
|
Part A and B
|
Up to 24 months
|
Safety/dose limiting toxicities (DLTs)
Time Frame: Up to 28 days
|
Part A and B
|
Up to 28 days
|
Antitumor activity as measured by the objective response rate (ORR)
Time Frame: Through study completion, an average of 24 months
|
Expansion Cohorts: • Diffuse large B-cell lymphoma (DLBCL) after failure of CAR-T therapy Part A |
Through study completion, an average of 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (Concentration of odronextamab)
Time Frame: Up to 10 months
|
Peak plasma concentration (Cmax) of odronextamab Part A and B |
Up to 10 months
|
Incidence of anti-drug antibodies (ADA) to odronextamab
Time Frame: Over time; up to approximately 15 months
|
Part A and B
|
Over time; up to approximately 15 months
|
Titer of ADA to odronextamab
Time Frame: Over time; up to approximately 15 months
|
Part A and B
|
Over time; up to approximately 15 months
|
Incidence of neutralizing antibodies (NAb) to odronextamab over time
Time Frame: Over time; Up to approximately 15 months
|
Part A and B
|
Over time; Up to approximately 15 months
|
Objective response rate (ORR)
Time Frame: Through study completion, an average of 24 months
|
For dose escalation portion and expansion cohorts:
For dose escalation and dose expansion cohorts:
|
Through study completion, an average of 24 months
|
Progression-free survival
Time Frame: Up to 48 months
|
Part A and B
|
Up to 48 months
|
Overall Survival
Time Frame: Until death or lost to follow-up/ withdrawal, approximately up to 48 months
|
Part A and B
|
Until death or lost to follow-up/ withdrawal, approximately up to 48 months
|
Duration of response (DOR)
Time Frame: Until progression, approximately up to 48 months
|
Part A and B
|
Until progression, approximately up to 48 months
|
Minimal residual disease (MRD) for patients with CLL
Time Frame: Up to 24 months
|
Part A
|
Up to 24 months
|
Duration of Complete Response (DOCR)
Time Frame: Until progression, approximately up to 48 months
|
Part B
|
Until progression, approximately up to 48 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Publications and helpful links
General Publications
- Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, Barnes JA, O'Brien SM, Chavez JC, Duell J, Rosenwald A, Crombie JL, Ufkin M, Li J, Zhu M, Ambati SR, Chaudhry A, Lowy I, Topp MS. Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339. doi: 10.1016/S2352-3026(22)00072-2. Epub 2022 Apr 1.
- Zhu M, Olson K, Kirshner JR, Khaksar Toroghi M, Yan H, Haber L, Meagher C, Flink DM, Ambati SR, Davis JD, DiCioccio AT, Smith EJ, Retter MW. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Clin Transl Sci. 2022 Apr;15(4):954-966. doi: 10.1111/cts.13212. Epub 2022 Jan 7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R1979-HM-1333
- 2015-004491-30 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityCompletedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Celgene CorporationTerminatedChronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic LeukemiaUnited States
-
Roswell Park Cancer InstituteWithdrawnRefractory Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia
-
Mayo ClinicNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage I Small Lymphocytic Lymphoma | Stage III Chronic Lymphocytic Leukemia and other conditionsUnited States
Clinical Trials on Odronextamab multiple dose levels
-
Astellas Pharma Europe B.V.CompletedPharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707France
-
Galapagos NVCompleted
-
Galapagos NVCompleted
-
ProDa BioTech, LLCNational Cancer Institute (NCI)RecruitingAdvanced Pancreatic Cancer | Solid Tumor MalignanciesUnited States
-
PfizerCompletedColitis, UlcerativeSpain, Belgium, Germany, Czech Republic, Norway, Denmark, Slovakia
-
PfizerCompleted
-
J2H BiotechCompletedNon-alcoholic SteatohepatitisKorea, Republic of
-
Beijing Tiantan HospitalRecruiting